ID MKN1 AC CVCL_1415 SY MKN-1; MKN 1 DR BTO; BTO_0002384 DR CLO; CLO_0050804 DR EFO; EFO_0002830 DR ArrayExpress; E-MTAB-783 DR ArrayExpress; E-MTAB-2706 DR ArrayExpress; E-MTAB-2770 DR ArrayExpress; E-MTAB-3610 DR BioSample; SAMN03473129 DR BioSample; SAMN10987827 DR cancercelllines; CVCL_1415 DR Cell_Model_Passport; SIDM00271 DR CGH-DB; 117-1 DR CGH-DB; 9019-4 DR ChEMBL-Cells; CHEMBL3307492 DR ChEMBL-Targets; CHEMBL614352 DR Cosmic; 733174 DR Cosmic; 801337 DR Cosmic; 848145 DR Cosmic; 848379 DR Cosmic; 887252 DR Cosmic; 888824 DR Cosmic; 897532 DR Cosmic; 908138 DR Cosmic; 922692 DR Cosmic; 926111 DR Cosmic; 1007600 DR Cosmic; 1090459 DR Cosmic; 1093296 DR Cosmic; 1187282 DR Cosmic; 1223586 DR Cosmic; 1436023 DR Cosmic; 1482076 DR Cosmic; 1627263 DR Cosmic; 1995508 DR Cosmic; 2443801 DR Cosmic; 2484957 DR Cosmic; 2807632 DR Cosmic-CLP; 908138 DR DepMap; ACH-000351 DR EGA; EGAS00001000610 DR EGA; EGAS00001000978 DR FANTOM5_SSTAR; 10614-108G2 DR GDSC; 908138 DR GEO; GSM552363 DR GEO; GSM562394 DR GEO; GSM827531 DR GEO; GSM844606 DR GEO; GSM887323 DR GEO; GSM888399 DR GEO; GSM1374680 DR GEO; GSM1670111 DR IARC_TP53; 998 DR JCRB; JCRB0252 DR KCLB; 80101 DR LiGeA; CCLE_128 DR LINCS_LDP; LCL-1917 DR Lonza; 1374 DR PharmacoDB; MKN1_936_2019 DR Progenetix; CVCL_1415 DR PubChem_Cell_line; CVCL_1415 DR RCB; RCB1003 DR Wikidata; Q54905820 RX CelloPub=CLPUB00581; RX CelloPub=CLPUB00584; RX DOI=10.1016/B978-0-12-333530-2.50014-9; RX PubMed=758928; RX PubMed=1370612; RX PubMed=1778766; RX PubMed=1933850; RX PubMed=6862145; RX PubMed=9290701; RX PubMed=11107048; RX PubMed=15723654; RX PubMed=15767549; RX PubMed=15900046; RX PubMed=20164919; RX PubMed=20215515; RX PubMed=22336246; RX PubMed=22460905; RX PubMed=24807215; RX PubMed=25343454; RX PubMed=25485619; RX PubMed=25877200; RX PubMed=25960936; RX PubMed=26589293; RX PubMed=27397505; RX PubMed=28196595; RX PubMed=29435981; RX PubMed=30894373; RX PubMed=30971826; RX PubMed=31068700; RX PubMed=31978347; RX PubMed=32847597; RX PubMed=34331011; WW Info; COPE; -; http://www.cells-talk.com/index.php/page/copelibrary?key=MKN-1 WW Info; MCLP; -; https://tcpaportal.org/mclp/ CC Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). CC Part of: COSMIC cell lines project. CC Part of: JFCR39 cancer cell line panel. CC Part of: JFCR45 cancer cell line panel. CC Part of: MD Anderson Cell Lines Project. CC Population: Japanese. CC Doubling time: 43-45 hours (CelloPub=CLPUB00584); 31 hours (PubMed=29435981). CC HLA typing: A*24:02,26:02; B*40:01,40:01; C*03:04,03:04; DQA1*04:01,04:01; DQB1*03:09,03:09; DRB1*11:01,03:17 (PubMed=25960936). CC HLA typing: A*24:02,26:02; B*40:01,40:01; C*03:04,03:04 (PubMed=26589293). CC Microsatellite instability: Stable (MSS) (Sanger). CC Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Val143Ala (c.428T>C); ClinVar=VCV000804214; Zygosity=Unspecified (PubMed=1370612; PubMed=11107048; PubMed=15900046). CC Omics: Genomics; DNA methylation analysis. CC Omics: Genomics; Whole exome sequencing. CC Omics: Phenotyping; CRISPR screening. CC Omics: Phenotyping; Drug screening. CC Omics: Proteomics; Expression; Reverse-phase protein array. CC Omics: Proteomics; Quantitative. CC Omics: Transcriptomics; Microarray. CC Omics: Transcriptomics; RNAseq. CC Omics: Variations; Array-based CGH. CC Omics: Variations; SNP array analysis. CC Genome ancestry: African=0.31%; Native American=0%; East Asian, North=81.4%; East Asian, South=15.4%; South Asian=0%; European, North=0.44%; European, South=2.44% (PubMed=30894373). CC Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029. ST Source(s): Cosmic-CLP=908138; JCRB=JCRB0252; KCLB=80101; PubMed=25877200; RCB=RCB1003 ST Amelogenin: X ST CSF1PO: 9,12 ST D13S317: 10,12 ST D16S539: 11,12 ST D18S51: 13,16 ST D21S11: 29 ST D3S1358: 15,17 ST D5S818: 11 ST D7S820: 10 ST D8S1179: 14 ST FGA: 20,23 ST Penta D: 10 ST Penta E: 21 ST TH01: 9 ST TPOX: 8 ST vWA: 16 DI NCIt; C5474; Gastric adenosquamous carcinoma OX NCBI_TaxID=9606; ! Homo sapiens (Human) SX Male AG 72Y CA Cancer cell line DT Created: 04-04-12; Last updated: 10-04-25; Version: 45 // RX CelloPub=CLPUB00581; RA Hojo H.; RT "Establishment of cultured cell lines of human stomach cancer origin RT and their morphological characteristics."; RL Niigata Igakkai Zasshi 91:737-763(1977). // RX CelloPub=CLPUB00584; RA Motoyama T., Hojo H., Suzuki T., Oboshi S.; RT "Evaluation of the regrowth assay method as an in vitro drug sensitivity RT test and its application to cultured human gastric cancer cell lines."; RL Acta Med. Biol. 27:49-63(1979). // RX DOI=10.1016/B978-0-12-333530-2.50014-9; RA Sekiguchi M., Suzuki T.; RT "Gastric tumor cell lines."; RL (In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.287-316; Academic Press; New York; USA (1994). // RX PubMed=758928; DOI=10.1038/bjc.1979.3; PMCID=PMC2009802; RA Kinjo M., Oka K., Naito S., Kohga S., Tanaka K., Oboshi S., Hayata Y., RA Yasumoto K.; RT "Thromboplastic and fibrinolytic activities of cultured human cancer RT cell lines."; RL Br. J. Cancer 39:15-23(1979). // RX PubMed=1370612; DOI=10.1016/S0006-291X(05)80133-0; RA Matozaki T., Sakamoto C., Matsuda K., Suzuki T., Konda Y., Nakano O., RA Wada K., Uchida T., Nishisaki H., Nagao M., Kasuga M.; RT "Missense mutations and a deletion of the p53 gene in human gastric RT cancer."; RL Biochem. Biophys. Res. Commun. 182:215-223(1992). // RX PubMed=1778766; DOI=10.1111/j.1349-7006.1991.tb01816.x; PMCID=PMC5918361; RA Takeshima E., Hamaguchi M., Watanabe T., Akiyama S., Kataoka M., RA Ohnishi Y., Xiao H.-Y., Nagai Y., Takagi H.; RT "Aberrant elevation of tyrosine-specific phosphorylation in human RT gastric cancer cells."; RL Jpn. J. Cancer Res. 82:1428-1435(1991). // RX PubMed=1933850; RA Yamada Y., Yoshida T., Hayashi K., Sekiya T., Yokota J., Hirohashi S., RA Nakatani K., Nakano H., Sugimura T., Terada M.; RT "p53 gene mutations in gastric cancer metastases and in gastric cancer RT cell lines derived from metastases."; RL Cancer Res. 51:5800-5805(1991). // RX PubMed=6862145; DOI=10.20772/cancersci1959.74.2_240; RA Naito S., Inoue S., Kinjo M., Tanaka K.; RT "Thromboplastic and fibrinolytic activities of cultured human gastric RT cancer cell lines."; RL Gann 74:240-247(1983). // RX PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D; RA Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., RA Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., RA Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.; RT "Screening the p53 status of human cell lines using a yeast functional RT assay."; RL Mol. Carcinog. 19:243-253(1997). // RX PubMed=11107048; DOI=10.1046/j.1440-1827.2000.01117.x; RA Yokozaki H.; RT "Molecular characteristics of eight gastric cancer cell lines RT established in Japan."; RL Pathol. Int. 50:767-777(2000). // RX PubMed=15723654; DOI=10.1111/j.1349-7006.2005.00016.x; PMCID=PMC11160020; RA Takada H., Imoto I., Tsuda H., Sonoda I., Ichikura T., Mochizuki H., RA Okanoue T., Inazawa J.; RT "Screening of DNA copy-number aberrations in gastric cancer cell lines RT by array-based comparative genomic hybridization."; RL Cancer Sci. 96:100-110(2005). // RX PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234; RA Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., RA Yamori T.; RT "Chemosensitivity profile of cancer cell lines and identification of RT genes determining chemosensitivity by an integrated bioinformatical RT approach using cDNA arrays."; RL Mol. Cancer Ther. 4:399-412(2005). // RX PubMed=15900046; DOI=10.1093/jnci/dji133; RA Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., RA Yamazaki K., Hamada J.-i., Tada M., Moriuchi T., Ishikawa Y., Kato Y., RA Tomoda H., Yamori T., Tsuruo T.; RT "p53-defective tumors with a functional apoptosome-mediated pathway: a RT new therapeutic target."; RL J. Natl. Cancer Inst. 97:765-777(2005). // RX PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113; RA Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., RA Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., RA Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., RA Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.; RT "Signatures of mutation and selection in the cancer genome."; RL Nature 463:893-898(2010). // RX PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662; RA Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., RA Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., RA Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., RA Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., RA Haber D.A.; RT "A genome-wide screen for microdeletions reveals disruption of RT polarity complex genes in diverse human cancers."; RL Cancer Res. 70:2158-2164(2010). // RX PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017; RA Kong D.-X., Yamori T.; RT "JFCR39, a panel of 39 human cancer cell lines, and its application in RT the discovery and development of anticancer drugs."; RL Bioorg. Med. Chem. 20:1947-1951(2012). // RX PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027; RA Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., RA Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., RA Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., RA Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., RA Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., RA Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., RA Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., RA Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., RA Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., RA Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., RA Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.; RT "The Cancer Cell Line Encyclopedia enables predictive modelling of RT anticancer drug sensitivity."; RL Nature 483:603-607(2012). // RX PubMed=24807215; DOI=10.1038/ncomms4830; PMCID=PMC4024760; RA Liu J.-F., McCleland M.L., Stawiski E.W., Gnad F., Mayba O., Haverty P.M., RA Durinck S., Chen Y.-J., Klijn C., Jhunjhunwala S., Lawrence M., RA Liu H.-B., Wan Y.-N., Chopra V.S., Yaylaoglu M.B., Yuan W.-L., Ha C., RA Gilbert H.N., Reeder J., Pau G., Stinson J., Stern H.M., Manning G., RA Wu T.D., Neve R.M., de Sauvage F.J., Modrusan Z., Seshagiri S., RA Firestein R., Zhang Z.-M.; RT "Integrated exome and transcriptome sequencing reveals ZAK isoform RT usage in gastric cancer."; RL Nat. Commun. 5:3830.1-3830.8(2014). // RX PubMed=25343454; DOI=10.1371/journal.pone.0111146; PMCID=PMC4208810; RA Choong M.-L., Tan S.-H., Tan T.-Z., Manesh S., Ngo A., Yong J.W.-Y., RA Yang H.H., Lee M.A.; RT "Molecular integrative clustering of Asian gastric cell lines revealed RT two distinct chemosensitivity clusters."; RL PLoS ONE 9:e111146.1-e111146.9(2014). // RX PubMed=25485619; DOI=10.1038/nbt.3080; RA Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., RA Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., RA Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., RA Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., RA Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., RA Settleman J., Seshagiri S., Zhang Z.-M.; RT "A comprehensive transcriptional portrait of human cancer cell RT lines."; RL Nat. Biotechnol. 33:306-312(2015). // RX PubMed=25877200; DOI=10.1038/nature14397; RA Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., RA Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., RA Neve R.M.; RT "A resource for cell line authentication, annotation and quality RT control."; RL Nature 520:307-311(2015). // RX PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981; RA Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.; RT "A catalog of HLA type, HLA expression, and neo-epitope candidates in RT human cancer cell lines."; RL OncoImmunology 3:e954893.1-e954893.12(2014). // RX PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878; RA Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., RA Loewer M., Sahin U., Castle J.C.; RT "TCLP: an online cancer cell line catalogue integrating HLA type, RT predicted neo-epitopes, virus and gene expression."; RL Genome Med. 7:118.1-118.7(2015). // RX PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469; RA Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., RA Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., RA Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., RA Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., RA Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., RA Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., RA Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., RA Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.; RT "A landscape of pharmacogenomic interactions in cancer."; RL Cell 166:740-754(2016). // RX PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076; RA Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., RA Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., RA Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., RA Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., RA Liang H.; RT "Characterization of human cancer cell lines by reverse-phase protein RT arrays."; RL Cancer Cell 31:225-239(2017). // RX PubMed=29435981; DOI=10.1002/ijc.31304; RA Kim H.J., Kang S.K., Kwon W.S., Kim T.S., Jeong I., Jeung H.-C., RA Kragh M., Horak I.D., Chung H.C., Rha S.Y.; RT "Forty-nine gastric cancer cell lines with integrative genomic RT profiling for development of c-MET inhibitor."; RL Int. J. Cancer 143:151-159(2018). // RX PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675; RA Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.; RT "An interactive resource to probe genetic diversity and estimated RT ancestry in cancer cell lines."; RL Cancer Res. 79:1263-1273(2019). // RX PubMed=30971826; DOI=10.1038/s41586-019-1103-9; RA Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., RA Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., RA Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., RA van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., RA Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.; RT "Prioritization of cancer therapeutic targets using CRISPR-Cas9 RT screens."; RL Nature 568:511-516(2019). // RX PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103; RA Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., RA McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., RA Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., RA Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., RA Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., RA Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., RA Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., RA Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., RA Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., RA Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., RA Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., RA Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., RA Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., RA Sellers W.R.; RT "Next-generation characterization of the Cancer Cell Line RT Encyclopedia."; RL Nature 569:503-508(2019). // RX PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254; RA Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd, RA Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., RA Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., RA Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., RA Sellers W.R., Gygi S.P.; RT "Quantitative proteomics of the Cancer Cell Line Encyclopedia."; RL Cell 180:387-402.e16(2020). // RX PubMed=32847597; DOI=10.1186/s12943-020-01251-0; PMCID=PMC7448342; RA Kanda M., Shimizu D., Sawaki K., Nakamura S., Umeda S., Miwa T., RA Tanaka H., Tanaka C., Hayashi M., Iguchi Y., Yamada S., Katsuno M., RA Kodera Y.; RT "Therapeutic monoclonal antibody targeting of neuronal pentraxin RT receptor to control metastasis in gastric cancer."; RL Mol. Cancer 19:131.1-131.14(2020). // RX PubMed=34331011; DOI=10.1038/s41388-021-01945-9; RA Kanda M., Shimizu D., Nakamura S., Sawaki K., Umeda S., Miwa T., RA Tanaka H., Inokawa Y., Hattori N., Hayashi M., Tanaka C., Nakayama G., RA Iguchi Y., Katsuno M., Kodera Y.; RT "Blockade of CHRNB2 signaling with a therapeutic monoclonal antibody RT attenuates the aggressiveness of gastric cancer cells."; RL Oncogene 40:5495-5504(2021). //